Early Discontinuations Changed the Safety Denominator in an Autism CBD Series
Safety findings from children who continued CBD-enriched cannabis should be read alongside the children who stopped early. In one autism series, two discontinuations preceded the reported restlessness rate among 31 continuing participants.
The continuing group was not the whole treated group
Bilge and Ekici describe 33 participating children, with two stopping treatment. One child stopped after increased stereotyped behavior; another had generalized seizures after starting treatment. Among the 31 who continued for at least three months, seven developed restlessness. Their doses were reduced, and restlessness decreased. Reporting tolerability only in the continuing group would omit the earlier events and the adjustments needed during follow-up.
The seizure event requires careful attribution
The authors report that seizures persisted after the preparation was discontinued and were subsequently controlled with valproic acid. That sequence documents a clinically important event associated in time with treatment. It does not by itself prove that the cannabis preparation caused the seizures, or prove that the event was unrelated. The cohort included children with pre-existing epilepsy or abnormal EEG findings, which further underscores the need for individual clinical context.
Tolerability involved selection and adaptation
The preparations were full-spectrum CBD products containing trace THC, and all participants were receiving antipsychotic medication. This was not a controlled isolated-CBD safety trial. Dose reduction in response to restlessness also means the observed follow-up reflects clinical adjustment, rather than an unchanged regimen tolerated by everyone. The useful account retains all starters, early stops, continuing participants and adverse events as separate categories. A small uncontrolled series cannot establish comprehensive developmental safety or rule out uncommon harms.
Related analysis: the broader findings and limitations of this research.
Research cited
Source used for this analysis: Bilge and Ekici (2021). CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature. Journal of Cannabis Research.
